The cell cycle machinery is regulated by cyclin dependent kinases and sets of activating and inhibitory proteins. The G1-S control mechanism is often deregulated in tumours supposedly leading to increased kinase activity, phosphorylation of substrates and subsequent S phase entrance. Increased kinase activity has been proposed to be essential in cell cycle aberrations, but few studies have actually shown enhanced kinase activity related to speci®c cell cycle defects in primary tumours. In the present study we have determined the cyclin E dependent kinase activity (cyclin E kinase ) in 59 primary breast cancers, using an H1-kinase assay, and related the activity to the expression of cyclin E, p27 and p21. In a subgroup of 48 tumours, we further characterized the association between cyclin E kinase , in vivo phosphorylation of the retinoblastoma protein (pRb) and proliferation. The cyclin E kinase correlated signi®cantly with cyclin E content and inversely with p27 and p21 expression. P27, but not p21, was associated with low cyclin E kinase in specimens with normal/low levels of cyclin E. At elevated cyclin E levels, suppression of cyclin E kinase seemed to require high levels of both p21 and p27. The cyclin E kinase correlated with the phosphorylation status of pRb as well as with proliferation. Surprisingly, pRb phosphorylation did not correlate with proliferation. Our results support that pRb is a substrate for cyclin E kinase in primary breast cancer and that deregulation of cyclin E and p27 act through increased CDK-kinase activity, but cyclin E associated events beside pRb phosphorylation might be rate-limiting for entrance into S phase.
Introduction
The G1/S transition in the cell cycle is an important checkpoint where the decision to enter S phase with succeeding cell division is taken. Cyclin dependent kinases (cdks) are central in this checkpoint and together with key proteins as cyclins and cdkinhibitors, regulatory protein complexes are formed (Draetta et al., 1994; Weinberg, 1995) . Aberrations in proteins involved in the G1-S transition are often observed in tumours and are thought to result in abnormal kinase activities, subsequent phosphorylation of the retinoblastoma protein (pRb), shortened G1/S transition and uncontrolled progression into S phase (Hunter and Pines, 1994; Sherr, 1996; Landberg and Roos, 1997) .
Cyclins D1 and E are two main G1 cyclins sequentially expressed during G1. pRb is an established substrate for cyclin D1 associated kinase activity, whereas the role for cyclin E regarding phosphorylation of pRb has not been fully clari®ed. Cyclin E expression increases in mid-late G1 at a time when pRb is extensively phosphorylated by at least two distinct cyclin Cdk-kinases Ko et al., 1992; Lundberg and Weinberg, 1998) . In yeast cells expressing human pRb but lacking G1 cyclins, both cyclin D1 and E were required for complete phosphorylation of pRb (Hatakeyama et al., 1994) . Cyclin D1 and cyclin E also phosphorylate partly dierent sites of pRb (Zarkowska and Mittnacht, 1997) . In summary, in vitro data suggest that pRb can be a substrate for cyclin E.
However, evidence for dierential roles for cyclin D1 and E, possible with additional substrate(s) for cyclin E parallel to or downstream of pRb has emerged. Cyclin E, but not cyclin D1, was required for G1/S transition in cells lacking functional pRb (Ohtsubo et al., 1995) . While premature expression of both cyclin D1 and cyclin E shortened G1/S transition, with additive eect when expressing both cyclins, only cyclin D1 expression led to hyperphosphorylated pRb (Resnitzky and Reed, 1995) . Using rat R12 ®broblasts, Lukas et al. (1997b) demonstrated that ectopic expression of cyclin E can override a G1 block imposed by either a phosphorylation-de®cient mutant pRb or overexpression of a dominant negative mutant DP-1, a heterodimeric partner of E2F. The recently described protein NPAT is also phosphorylated by cyclin E/cdk2 and interestingly, overexpression of NPAT in U2OS cells accelerated S phase entrance and the eect was enhanced by coexpression with cyclin E/cdk2 (Zhao et al., 1998) . This suggests that additional substrates besides pRb are involved in the control of the G1/S transition. p21 and p27 belong to the cip/kip family of cdkinhibitors, both having inhibitory eects on several cyclin-dependent kinases in vitro. The cyclin E/Cdk2 complex can consequently be inactivated by binding of p27 or multiple p21, causing G1 arrest due to absent pRb phosphorylation (Zhang et al., 1994; Sherr and Roberts, 1995) . A number of studies have demonstrated a p53 dependent upregulation of p21 in breast cancer (Wakasugi et al., 1997; Bukholm et al., 1997; Ellis et al., 1997; Jiang et al., 1997) but genetic changes in the p21 gene are rare (Mousses et al., 1995; Lukas et al., 1997a) . p27 accumulates in G0 cells (Coats et al., 1996) but in response to mitogens, p27 levels drop and cells can enter active cell cycle (Kato et al., 1994; Nourse et al., 1994) . p27 is thought to be regulated mainly at the post-translational level Hengst and Reed, 1996) and genetic alterations in the p27 gene or variations in mRNA levels are infrequent in tumours (Ferrando et al., 1996; Catzavelos et al., 1997; Fredersdorf et al., 1997) . Reduced p27 levels are nevertheless observed in human tumours (Catzavelos et al., 1997; Porter et al., 1997; Tan et al., 1997) potentially explained by alterations in p27 directed ubiquitin/proteosome degradation pathways (reviewed in Spataro et al., 1998) .
The signi®cance of cyclin E dependent kinase activity (cyclin E kinase ) in relation to the expression of cyclins and cdk-inhibitors in transformed cells have mainly been studied in cell lines. We have previously demonstrated a strong impact of cyclin E overexpression in breast cancer on prognosis (Nielsen et al., 1996) and associations between cyclin E and D1 deregulation with inactivation of pRb (Nielsen et al., 1997) . In this study we have characterized the relation between the cyclin E kinase , determined by an Histone H1-kinase assay, and the expression of cyclin E, p27 and p21 in 59 primary breast cancer samples. In order to elucidate pRb as an in vivo substrate for cyclin E kinase and if the pRb pathway is associated with proliferation, pRb phosphorylation and fraction of cycling tumour cells were determined in a subgroup of 48 samples. In summary, our results support that cyclin E, p27 and p21 aect cyclin E kinase in primary breast cancer and that pRb is a substrate for cyclin E. We also show that other pathway(s) besides pRb phosphorylation probably are rate limiting for S phase entrance.
Results

Cyclin E kinase determination
In order to obtain reproducible determinations of cyclin E kinase in frozen tumour material, substantial care was taken to optimize the extraction procedure and immunoprecipitation method and various assays were tested on cell lines and primary tumours (data not shown). The speci®city of the cyclin E antibody in the immunoprecipitation step preceding the kinase assay, was tested by a control agarose-conjugated anti-cyclin D1, IgG1 antibody. As shown in Figure  1a , cyclin E was not precipitated by anti-cyclin D1 and anti-cyclin E did not precipitate cyclin D1. To determine if cyclin E immunoprecipitates contained cdk-inhibitors, a set of tumours were immunoprecipitated and analysed by Western blotting for possible co-precipitation of cyclin E, p21 and p27. As presented in Figure 1b , p27 was present in the cyclin E complex of all ®ve tumours examined whereas p21 was visualized in one tumour. Cdk2 was also detected in the complexes (data not shown).
Cyclin E kinase was determined in 59 breast cancer tumour specimens by the Histone H1 kinase assay (Figure 2a ) and the activity was expressed relative to a cell line standard. Relative cyclin E kinase values varied from 0.11 to 6.62, (Figure 2b ). For the comparison between cyclin E kinase and the expression of cyclin E, p27 and p21 illustrated below in Figure 5 , the tumours were divided into three groups with respect to the distribution of kinase activity. High cyclin E kinase was de®ned as a relative activity above 0.31. Tumours displaying lower activity (40 out of 59, 68%) were divided into two equal groups, separating tumours with low and intermediate activities, respectively. The cut os used are indicated as dotted lines in Figure 2b .
Cyclin E, p27 and p21 determination
The cyclin E content in a series of 114 primary breast cancer samples has previously been characterized by a b Figure 1 (a) Immunoprecipitates (IP) of a primary breast cancer (U239), using cyclin E and cyclin D1 antibodies, were analysed by Western blot for the presence of cyclin E (upper panel) and cyclin D1 (lower panel). Cyclin E was not immunoprecipitated by cyclin D1 antibodies and cyclin E antibodies did not immunoprecipitate cyclin D1. The band marked with an asterisk in the cyclin D1 immunoprecipitate was not detected in a Western blot using whole tumour extracts and was considered to represent a part of the heavy chain of the cyclin D1 antibody used in the IP step. (b) Cyclin E immunoprecipitates (IP) of ®ve breast cancer samples (U158 ± U245) followed by Western blot analyses of cyclin E, p27 and p21. The cell line T47D is included as a control in the Western blot analyses (+primary antibodies) Western blotting (Nielsen et al., 1996) . The present tumour material represents a subset of these tumours including the majority of breast cancer samples with high cyclin E levels (40.5) and a randomly selected approximately equally sized group of tumours with lower cyclin E expression. Examples of cyclin E Western blots are shown in Figure 3 . All isoforms of cyclin E (Keyomarsi et al., 1995) , also detected in anti-cyclin E immunoprecipitates (Figure 1 ), were included in the densitometric analysis of cyclin E (Nielsen et al., 1996) . The expression of p21 varied from 50.1 to 50% positive cells with variations in staining intensity from barely detectable to intense. The tumour material was divided into three equally sized groups regarding p21 positivity, using cut os at 1 and 5% positive cells. The immunohistochemical expression of p27 has been detailed earlier (Nielsen et al., 1999) and in summary, 5 ± 90% positive nuclei were observed with the majority of tumours expressing more than 50% positive cells. Seventeen out of 59 (29%) tumours expressed less than 50% p27 positive tumour cells and were de®ned as tumours with low expression (Catzevelos et al., 1997) . In four of these tumours (7%), the expression was lower than 25%. As adjacent normal breast epithelium expressed 50 ± 90% p27 positive cells (data not shown) we could not securely subdivide the large group of tumours with high p27 expression. The staining intensity of p27 was for most cases similar in malignant and surrounding non-malignant cells or normal epithelium. Examples of immunohistochemical stainings of p21 and p27 are shown in Figure 3b and c.
Cyclin E kinase in relation to cyclin E, p21 and p27 expression
The cyclin E expression correlated signi®cantly to the cyclin E kinase (P50.0001) as illustrated in Figure 4a . However, the major population of tumours with a relative cyclin E content less than 0.5 showed limited spread in kinase activity whereas the cyclin E kinase displayed a more dispersed and higher expression among tumours with high cyclin E expression. Tumours with low, intermediate or high p21 expression did not dier signi®cantly in kinase activity (P=0.098) whereas specimens with low p21 (51% positive cells) had a signi®cantly higher kinase activity compared with tumours with intermediate and high p21 (41% positive cells) (P=0.050). The 1% cut o was therefore used to denote low and high expression of p21 in relation to kinase activity ( Figure 4b ). As illustrated in Figure 4c , tumours with low and high expression of p27 diered considerably in cyclin E kinase (P50.0001). There was no signi®cant association between p27 and p21 expression (P=0.120) but an inverse correlation was observed between cyclin E and p21 (P=0.038) and between cyclin E and p27 expression (P=0.022, not shown in the Figures).
Considering that low expression of cyclin E as de®ned above, probably corresponded to the normal variation in cyclin E expression observed in tumours due to proliferation dierences and high cyclin E might represent aberrant expression, we analysed the expression of cyclin E kinase in these two tumour groups. Surprisingly, there was no signi®cant association between cyclin E and the cyclin E kinase in the subgroup of tumours with low cyclin E (P=0.559, n=35) but a borderline signi®cance was observed in the group with high cyclin E expression (P=0.055, n=24). P27 displayed nevertheless a signi®cant correlation to cyclin E kinase within both subgroups (P=0.006 and P=0.030, respectively). P21 was associated with cyclin E kinase among tumours expressing high levels of cyclin E (P=0.010) but not within tumours with low cyclin E expression (P=0.289).
To illustrate the combined eect of cyclin E, p21 and p27 expression on the cyclin E kinase , the cyclin E content was plotted versus p21 and p27 divided into four groups (a, low levels of p21 and p27; b, high p21 low p27; c, low p21 high p27 and d, high levels of both) and low, intermediate and high relative cyclin E kinase was indicated ( Figure 5 ). Among tumours with low cyclin E expression, only alterations in the p27 expression was signi®cantly associated with dierence in cyclin E kinase . Twenty out of 28 tumours, expressing high p27 (groups c and d), had low cyclin E kinase in contrast to no tumour out of seven with low p27 expression (groups a and b). Low cyclin E kinase was exclusively found among tumours with low cyclin E and high p27 expression and consequently, at high cyclin E expression all tumours had either high or intermediate cyclin E kinase . Interestingly, combined high p21 and p27 expression (and high cyclin E) was associated with intermediate kinase activity (eight out of ten tumours) whereas in tumours with either low levels of p21 or p27, or both, intermediate kinase activity was rare (one out of 14) and high kinase activity was instead observed. Thus, at high cyclin E expression, high levels of both p21 and p27 were required to suppress the cyclin E kinase .
Cyclin E kinase in relation to phosphorylation of pRb and proliferation
As pRb is a potential substrate for cyclin E, we wanted to examine the relation between cyclin E kinase and the degree of in vivo pRb phosphorylation, as well as proliferation using Ki-67 labelling index (LI) as a marker. Phosphorylation levels were determined by Western blotting and the optical density of the slower migrating form of pRb (illustrated in Figure 3a) was divided with the total pRb content. Only tumours with functional pRb were included in these studies and six tumours lacking nuclear immunohistochemical pRb staining and considered pRb inactivated with aberrant phosphorylation patterns (Nielsen et al., 1997) were excluded. Five additional tumours were also excluded due to technical problems in the immunohistochemical procedure. A total of 48 tumours were therefore analysed for associations between cyclin E kinase , pRb phosphorylation and Ki-67 LI. The cyclin E kinase correlated signi®cantly with pRb phosphorylation (P=0.005) but unexpectedly there was no correlation between pRb phosphorylation and Ki-67 LI (P=0.793) as illustrated in Figure 6a and b.
To evaluate if cyclin E dependent phosphorylation of pRb is the rate limiting step for S phase entrance, or if other cyclin E associated pathways could be indicated, the relation between cyclin E kinase and proliferation was evaluated. Ki-67 LI correlated signi®cantly with cyclin E kinase (P=0.010, Figure 6c ) as well as with cyclin E expression as reported elsewhere (Nielsen et al., 1998, submitted) . These data, and the lack of correlation between pRb phosphorylation and proliferation, indicated that cyclin E dependent pathways other than pRb phosphorylaton was rate limiting for S phase entrance in primary breast cancer. A model based on the association between the characterized parameters in this study is shown in Figure 7 .
Discussion
Deregulation of the G1/S checkpoint is common in cancer and might even be a prerequisite for tumour development. We have in this study focused on cyclin E associated defects in breast cancer and explored potential associations between cyclin E, p27 and p21 expression and cyclin E kinase . Potential downstream eects of the cyclin E kinase , as pRb phosphorylation and proliferation, were also detailed. The expression of p21 and p27 was characterized by immunohistochemistry whereas cyclin E was evaluated by Western blotting as described earlier (Nielsen et al., 1996) . P21 is generally expressed in a small number of tumour cells and immunohistochemistry is a favourable method to detect moderate upregulation of p21. In contrast to p21, p27 is expressed at high levels in lymphocytes and in normal non-proliferating mammary epithelial cells serving as internal control cells in the immunohistochemical evaluation of p27 expression (Porter et al., 1997) . Nevertheless, the high p27 expression in non-malignant cells could potentially mask variations in p27 expression in tumours if the expression was analysed by Western blotting and we therefore used immunohistochemical evaluation.
Few studies have investigated the associations between cyclin E, p21 or p27 protein levels and cyclin E kinase in tumours. Keyomarsi et al. (1995) demonstrated that cyclin E kinase was considerably higher in ®ve breast cancer cell lines with elevated levels of cyclin E than in two cell lines with moderate levels of cyclin E (Keyomarsi et al., 1995). An inverse correlation between cyclin E kinase and p27 has also been observed in a limited study of primary breast cancer (Catzavelos et al., 1997) but the relation between cyclin E kinase and G1-S transition defects has not been detailed in larger patient materials.
In this study, we have shown that cyclin E kinase in breast cancer correlated signi®cantly with the expression of cyclin E, p21 and p27, respectively. Interestingly, p27 displayed the most prominent eect on cyclin E kinase . Similar results were obtained by Loda et al., analysing cdk2 kinase activity in 15 colorectal a carcinomas . We have earlier reported that cyclin E was heavily upregulated in a fraction of breast cancers and these tumours were highly aggressive compared to tumours with low/ normal cyclin E expression (Nielsen et al., 1996) . The association between cyclin E, p27, p21 and cyclin E kinase was therefore analysed separately in these two groups of tumours. Surprisingly, cyclin E did not correlate with cyclin E kinase in the subgroup of low/normal cyclin E but a borderline signi®cance was observed in the group with higher cyclin E expression. In contrast, the p27 expression was signi®cantly associated with cyclin E kinase in both subgroups. Instead of being the main regulator of the cyclin E kinase , we therefore suggest that cyclin E is a rough activator of the cyclin E/cdk2 complex and that the ®ne-tuning is a result of the inhibitors p21 and p27. Our results further show that the regulation of cyclin E kinase by cyclin E, p21 and p27 diers in tumours depending on their cyclin E levels. P27, but not p21, aected the cyclin E kinase in tumours with low cyclin E, but inhibition at increased cyclin E expression required high levels of both p21 and p27. Even though both p21 and p27 are potent inhibitors of cyclin E kinase in vitro, diverse roles for p21 and p27 have been suggested. Mice lacking the p27 gene exhibited increased body size and multiorgan hyperplasia (Fero et al., 1996; Kiyokawa et al., 1996) not observed in mice lacking p21 (Deng et al., 1995) . p27 has been proposed to be the primary regulator of cdk activity for cells entering or leaving quiescence while p21 may regulate the cdk activity in actively cycling cells (Nourse et al., 1994) . The fact that a majority of the malignant cells in the present breast cancer material were non-proliferating and the regulation of cell cycle exit/entrance probably dominated, might explain why p27 was the main moderator of the cyclin E kinase as observed in this study. Consistently, p21 contributed to the regulation of cyclin E kinase in tumours with high cyclin E expression and increased proliferation, and consequently larger fractions of actively cycling cells. Studies have been initiated to determine if tumours with combined high cyclin E expression and p53 mutations, with a subsequent inability to induce p21 expression, might be more aggressive than tumours with functional p53 and combined high p21 and cyclin E expression.
The regulatory mechanisms linking p27 and cyclin E protein expression in transformed cells are not fully clari®ed. Non-transformed human and mouse mammary epithelial cell lines, transfected with cyclin E, showed increased p27 expression, unaected cyclin E kinase and growth inhibition (Sgamboto et al., 1996 (Sgamboto et al., , 1997 proposing a compensatory mechanism balancing the activation by cyclin E. High expression of p27 has also been observed in a limited number of breast cancer cell lines (Fredersdorf et al., 1997) . These cells were highly proliferative suggesting a mechanism by which some tumour cells tolerate elevated levels of the inhibitor without aecting cell growth. We could not in this study securely de®ne tumours with potential overexpression of p27, but several tumours with high p27 expression were yet highly proliferative.
The retinoblastoma protein (pRb) is a potential substrate for cyclin E, as discussed earlier (Hinds et al., 1992; Hatakeyama et al., 1994; Weinberg, 1995) . However, no studies have examined the relation between cyclin E kinase and the degree of pRb phosphorylation in primary tumours. Our results demonstrating a signi®cant association between cyclin E kinase and in vivo pRb phosphorylation, support that pRb is a substrate for cyclin E associated kinases. The phosphorylation of pRb is associated with G1/S restriction point control and the pRb pathway has therefore been directly linked to cell growth and proliferation Nevins et al., 1997) . However, we did not observe any association between pRb phosphorylation and proliferation in this study, suggesting that other events besides pRb phosphorylation are rate limiting for S phase entrance. Several studies have also shown that the G1/S transition may be regulated by pRbindependent mechanisms (Ohtsubo et al., 1995; Lukas et al., 1997b) . NPAT is a newly described substrate to (Zhao et al., 1998) implicated in the control of S phase entrance. When the phosphorylation status of NPAT as well as other substrates potentially involved in the G1-S transition have been clari®ed in tumour cells, the complex orchestration commanding cells to S phase might be revealed. In this report we present a model system based on primary breast cancer samples where potential substrates to cyclin E kinase can be tested. We have observed a correlation between cyclin E kinase and proliferation and we can therefore continue to test the associations between proliferation and degree of phosphorylation of other potential substrates in order to ®nd the rate limiting substrates. These types of correlative analyses using primary tumours can therefore be useful in the characterization of mechanisms by which G1-S transition defects act through.
Inactivation of pRb probably represents the most severe G1-S transition defects in breast cancer, resulting in highly proliferative and clinically aggressive tumours (Nielsen et al., 1997; Lukas et al., 1995) . All six pRb inactivated tumours in this study expressed high levels of cyclin E as well as cyclin E kinase (data not shown) but due to the low numbers of tumours in this group, any de®nite conclusions concerning associations between cyclin E kinase and proliferation cannot be made. Further studies have to elucidate if tumours lacking pRb favour any speci®c alternative substrate to pRb.
As detailed in another report the cyclin E expression in the present cancer material correlated strongly with proliferation (Nielsen et al., 1999) consistent with other studies on colorectal and breast carcinomas (Yasui et al., 1996; Scott et al., 1997) . This strong association, observed in the entire material as well as in tumours with low and high cyclin E (data not shown) raises the question whether cyclin E may be associated with other uncharacterized complexes involved in G1/S transition control. Future studies have to clarify the exact mechanisms by which cyclin E in¯uence S phase entrance.
In this study we have investigated the associations between aberrant expression of cyclin E, p27 and p21 and the cyclin E kinase in a larger material of primary breast cancer samples. The cyclin E kinase was further related to the degree of in vivo pRb phosphorylation and proliferation in order to elucidate downstream eects of the kinase. In summary, our results support that (1) cyclin E, p27 and p21 all in¯uence the cyclin E kinase , with p27 as the most prominent regulator, (2) pRb is a substrate for cyclin E and (3) phosphorylation of other substrates besides pRb might be rate limiting for S phase entrance.
Materials and methods
Tumour samples
The patient material represents a partially selected group of 59 women with primary breast cancer, treated at UmeaÊ University Hospital during 1988 ± 1991. According to the classi®cation from The International Union Against Cancer 12 patients had stage I, 37 patients had stage II, one patient had stage III and six patients had stage IV. Three patients had unknown disease stage owing to unknown tumour size or axillary node status. No patient received any antitumoural therapy before surgery. Tumours specimen were snap frozen in liquid nitrogen within 15 min after surgery and stored in 7808C.
Immunohistochemistry
Paran embedded sections were dried, deparanized, rehydrated and microwave treated according to standard procedures before being processed in an automatic immunohistochemistry staining machine (Ventana 320-202, Ventana inc., AZ, USA) using monoclonal antibodies against p21 (Waf-1 (Ab-1), Calbiochem, UK) and p27 (K25020, Transduction Laboratories, KY, USA). Staining of pRb using polyclonal antibodies (C15, Santa Cruz, CA, USA), as well as Ki67 using MIB-1 antibodies I (Immunotech, France) and ABC kits (Vector Laboratories inc., CA, USA) have been described elsewhere (Nielsen et al., 1996) P21 was evaluated by counting at least 2000 cells. As adjacent normal breast epithelium or lymphocytes did not express p21, samples with complete lack of staining were excluded from the analyses. For evaluation of p27, at least 300 cells were counted. Normal surrounding tissues and lymphocytes were p27 positive and served as internal controls for the p27 staining.
Western blotting
As described earlier, 40 mg of total protein were separated on SDS-polyacrylamide gels and separated proteins were transferred to nitrocellulose membranes (Nielsen et al., 1996) . Membranes were blocked in phosphate buered saline containing 5% dried milk and 0.1% tween 20 and then probed for 1 h with monoclonal or polyclonal a-cyclin E (HE-12 and C19, Santa Cruz, CA, USA), a-pRb (IF8, Santa Cruz), anti-p21 (Waf-1 (Ab-1), Calbiochem, UK), a-p27 (K25020, Transduction Laboratories, KY, USA), a-cyclin D1 (Ab-3, Calbiochem, UK) or a-cdk2 (M2, Santa Cruz). After washing, membranes were incubated with peroxidase conjugated secondary antibodies for 1 h and proteins were detected using ECL or ECL+ detection systems (Amersham, UK). Optical densities of the ECL and ECL+ ®lms were determined by a densitometer (Molecular Dynamics, CA, USA). The percentage of phosphorylated pRb was calculated by dividing the optical density of the slower migrating phosphorylated band with the total amount of pRb.
Immunoprecipitation and histone H1 kinase assay
Frozen tumour samples were pulverized using a dismembrator (Mikrodismembrator U, B Braun Biotech International, Germany) and resolved in 1% RIPA buert (50 mM Tris-HCl pH 7.5, 1% w/v) Sodium Deoxycholate, 1% Triton X-100, 150 mM NaCl, 25 mM NaF, 2 mg/ml leupeptin and apropeptin, 0.1 mg/ml PMSF, 1 mg/ml pepstatin and 1 mM sodium pyrophosphate). Samples were then sonicated (Soni®er cell disruptor B-30, Branson Sonic Power Co, CNT, USA) 2630 s on ice at 10% pulse mode and centrifuged at 14 000 r.p.m. for 30 min. Aliquots of the supernatant were stored at 71208C until further analyses. Total protein concentration was determined by the detergentcompatible BCA (bicinchoninic acid) protein assay (Pierce, IL, USA). 250 mg of total protein was incubated with 30 ml of monoclonal agarose-conjugated antibodies against cyclin E (HE-111, Santa Cruz, CA, USA) or cyclin D1 (HD-11, Santa Cruz) for 2 h at 48C. Agarose pellets were washed four times using 1% RIPA buer and four times with a kinase buer (30 mM Tris-HCl 7.5, 6 mM MgCl, 0.1 mg/ml Bovine Serum Albumin (BSA) and 1 mM Dithiothreitol (DTT). Immunoprecipitated proteins were detected using Western blotting as described above. For the kinase assay, agarose pellets were incubated for 30 min with 60 mM ATP and 2.5 mg of Histone H1 (Boeringer-Mannheim, Germany) and 5 mCi [g 32 ]ATP (total volume of 20 ml) at 378C. Samples were then boiled for 10 min with SDS-polyacrylamide loading buer and separated on 11% SDS-polyacrylamide gels that were subsequently boiled for 20 min in 5% trichloroacetic acid (TCA) and dried. Evaluations of radioactively phosphorylated proteins were performed using a Molecular Imager and Molecular Analyst software (Bio-Rad Lab, CA, USA). As standard, 200 mg of HeLa extracts were immunoprecipitated as above and three HeLa immunoprecipitates were measured in parallel to tumour samples at each occasion. Relative kinase activities were then calculated by dividing the activity of the tumour samples by the mean of the HeLa samples.
Statistical methods
Associations between linear parameters were calculated using Spearman's two-tail signi®cance test. The KruskalWallis non-parametric signi®cance test was applied when comparing a linear and a grouped parameter. Comparisons between groups were performed with the log-rank test and all calculations using SPSS version 6.0 (SPSS, IL, USA).
